Important note: Information in this article was accurate in June 2003. The state of the art June have changed since the publication date. |
AIDSWEEKLY Plus; Monday, June 16, 2003
Michael Greer, Senior Medical Writer
"Vaccines that elicit systemic and mucosal immune responses should be the choice to control human immunodeficiency virus (HIV) infections," argued M. Magdalena Gherardi and colleagues at the Centro Nacional de Biotecnologia in Madrid and the Mount Sinai School of Medicine in New York City. "We have previously shown that prime-boost immunizations with influenza virus Env and vaccinia virus (VV) WR Env recombinants induced an enhanced systemic CD8+ T-cell response against HIV-1 Env antigen."
The use of a highly attenuated modified VV Ankara (MVA) vector as a booster enhanced the performance of this regimen, Gherardi and coauthors found.
The researchers compared the immunogenicity of VV WR Env and MVA Env boosters in mice primed with influenza virus Env. Both boosters elicited robust Env-specific cytotoxic T-cell activity when administered by the intraperitoneal route, they noted.
However, the cytotoxic T-cell response in the genital lymph nodes was 2.5 times greater in MVA-boosted animals compared to their VV WR-boosted counterparts, study data showed. Splenic cytotoxic T-cell activity was also slightly higher after MVA boosting.
Both regimens produced heightened Th1-type activity against Env compared to control mice ( Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol. 2003 Jun;77(12):7048-57.
"These results demonstrate that the combination Flu/MVA in prime-booster immunization regimens is an effective vaccination approach to generate cellular immune responses to HIV antigens at sites critical for protective responses," Gherardi and collleagues concluded.
The corresponding author for this report is Mariano Esteban, Centro Nacional de Biotecnologia, Campus Universidad Autonoma, 28049 Madrid, Spain. E-mail: mesteban@cnb.uam.es.
Key points reported in this study include:
Prime-boost HIV vaccine regimens using recombinant influenza virus and vaccinia virus vectors are effective in mice
Priming with flu virus followed by boosting with modified vaccinia virus Ankara (MVA) vectors expressing Env produced robust anti-Env cytotoxic T-cell responses
Similar results were seen when recombinant vaccinia virus WR was used as a booster
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Gherardi MM, Najera JL, Perez-Jimenez E, et al., "Prime-Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes", J Virol. 2003 Jun;77(12):7048-57.
PubMED Related articles Search
030616
AW030608
Copyright © 2003 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.